Phathom Pharmaceuticals Inc (Phathom Pharmaceuticals) develops and commercializes medicines for the treatment of gastrointestinal (GI) diseases. The company's pipeline products include vonoprazan, an oral small-molecule potassium-competitive acid blocker (P-CAB). It also evaluates its vonoprazan in combination with antibiotics for the treatment of Helicobacter pylori infection. It also has a research and development center to develop GI therapeutics, including anti-secretory agents in the pharmaceutical industry market. The company operates in the US and Canada. Phathom Pharmaceuticals is headquartered in Buffalo Grove, Illinois, the US.
Headquarters
United States of America
Address
100 Campus Drive, Suite 102, Florham Park, New Jersey, 07932
Website
www.phathompharma.com
Telephone
1 302 6365400
No of Employees
452
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHAT (NASD)
Revenue (2022)
$682,000
EPS
XYZ
Net Income (2022)
XYZ
-2%
(2022 vs 2021)
Market Cap*
$554.8M
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Phathom Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Product: |
| Vonoprazan Drug- H. Pylori Infection, Erosive Esophagitis and Gastroesophageal Reflux Disease (GERD) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In December, the company received approval from FDA for VOQUEZNA (vonoprazan) as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) in adults. |
| 2023 | Regulatory Approval | In October, the company secured approval from the U.S. Food and Drug Administration for Prior Approval Supplement for the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of Helicobacter pylori (H. pylori) infection in adults. |
| 2023 | Regulatory Approval | In February, the company's VOQUEZNA, TRIPLE PAK and VOQUEZNA DUAL PAK secured an approval in the US for the treatment of H. pylori infection. |
Competitor Comparison
| Key Parameters | Phathom Pharmaceuticals Inc | Cosmo Pharmaceuticals NV | RedHill Biopharma Ltd | Verrica Pharmaceuticals Inc | Salix Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | Israel | United States of America | United States of America |
| City | Florham Park | Dublin | Tel Aviv-Yafo | West Chester | Raleigh |
| State/Province | New Jersey | - | - | Pennsylvania | North Carolina |
| No. of Employees | 452 | 325 | 53 | 100 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Terrie Curran | President; Director; Chief Executive Officer | Executive Board | 2019 | 54 |
| Azmi Nabulsi, M.D. | Chief Operating Officer | Senior Management | 2019 | 63 |
| Joe Hand | Chief Administrative Officer | Senior Management | 2019 | - |
| Eckhard Leifke, M.D., Ph.D. | Chief Medical Officer | Senior Management | - | - |
| Larry Miller | General Counsel | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward